Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy
Acta cir. bras; 34 (12), 2019
Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawba...
Carcinoma/tratamiento farmacológico, Carcinoma/patología, Membrana Corioalantoides/patología, Ilustración Médica, Terapia Neoadyuvante, Siembra Neoplásica, Neoplasias Experimentales/tratamiento farmacológico, Neoplasias Experimentales/patología, Fenotipo, Neoplasias de la Vejiga Urinaria/tratamiento farmacológico, Neoplasias de la Vejiga Urinaria/patología, Urotelio/patología